Why the study?
ICG001 impedes beta-catenin-mediated gene transcription to protect the heart and kidney, but its mechanisms for preventing heart failure remain unclear.
Does ICG001 prevent heart failure, cardiac hypertrophy, and fibrosis in a mouse model of pressure overload?
Does ICG001 prevent heart failure, cardiac hypertrophy, and fibrosis in a mouse model of pressure overload?
Answers are grounded in this paper and cite their sources.
Inhibition of the Wnt/β-catenin signaling pathway with ICG001 prevents pressure overload-induced heart failure, cardiac hypertrophy, and fibrosis in mice by reducing macrophage accumulation and regulating KLF5.
In heart failure (HF) caused by hypertension, the myocyte size increases, and the cardiac wall thickens. A low-molecular-weight compound called ICG001 impedes β-catenin-mediated gene transcription, thereby protecting both the heart and kidney. However, the HF-preventive mechanisms of ICG001 remain unclear. Hence, we investigated how ICG001 can prevent cardiac hypertrophy and fibrosis induced by transverse aortic constriction (TAC). Four weeks after TAC, ICG001 attenuated cardiac hypertrophy and fibrosis in the left ventricular wall. The TAC mice treated with ICG001 showed a decrease in the following: mRNA expression of brain natriuretic peptide (Bnp), Klf5, fibronectin, β-MHC, and β-catenin, number of cells expressing the macrophage marker CD68 shown in immunohistochemistry, and macrophage accumulation shown in flow cytometry. Moreover, ICG001 may mediate the substrates in the glycolysis pathway and the distinct alteration of oxidative stress during cardiac hypertrophy and HF. In conclusion, ICG001 is a potential drug that may prevent cardiac hypertrophy and fibrosis by regulating KLF5, immune activation, and the Wnt/β-catenin signaling pathway and inhibiting the inflammatory response involving macrophages.
No takes yet. Share an insight, caveat, or question.
Methatham et al. (2021) studied Heart failure (pressure overload-induced) (n=40). ICG001 vs. Vehicle (DMSO) was evaluated on Left ventricular ejection fraction (LVEF) at 4 weeks after TAC (p=<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: